GlassScriptPhysician profile
Francis Mah
NPI 1528032620
$1,117,050.83
in general payments reported to CMS, 2019-2025
39 companies · $225K in 2025
The $225K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214K · 2020: $139K · 2021: $144K · 2022: $156K · 2023: $110K · 2024: $129K · 2025: $225K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $192K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Honoraria: $67K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $60K · Travel and Lodging: $33K · Food and Beverage: $20K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $192,203.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,414.97 |
| Honoraria | $67,200.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $59,712.50 |
| Travel and Lodging | $32,731.38 |
| Food and Beverage | $19,870.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $162,407.27 | 2022-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Oyster Point Pharma, INC. | $142,860.99 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Kala Pharmaceuticals, INC. | $93,992.81 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $89,398.23 | 2019-2025 | Tecnis Iol, Healon Duet Pro, Compact Intuitiv |
| Ani Pharmaceuticals, INC. | $79,069.98 | 2024-2025 | Purified Cortrophin Gel, Yutiq |
| Novartis Pharmaceuticals Corporation | $73,583.24 | 2019-2023 | |
| Allergan, INC. | $66,028.71 | 2019-2022 | |
| Dompe US, INC. | $64,662.13 | 2019-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $64,126.97 | 2020-2025 | Cequa |
| Alcon Vision LLC | $50,617.00 | 2019-2025 | Tryptyr, Argos, Clareon |
| Shire North American Group INC | $48,370.92 | 2019 | |
| Mallinckrodt Hospital Products INC. | $41,201.76 | 2020-2025 | Acthar |
| Abbvie INC. | $30,152.86 | 2022-2025 | |
| Glaxosmithkline, LLC. | $28,439.02 | 2021-2022 | |
| Alcon Research LLC | $10,933.74 | 2022-2025 | Tryptyr, Clareon, Lensx |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $10,409.56 | 2019-2025 | Artevo 800, Visumax, Veracity Surgical |
| Glaukos Corporation | $9,216.52 | 2021-2025 | Epioxa, Travoprost Intraocular Implant - Idose, Ce-Marked Kxla System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $8,743.00 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $7,887.00 | 2022-2023 | Flarex |
| Tarsus Pharmaceuticals, INC. | $5,675.68 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $5,140.32 | 2019-2023 | Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $4,446.20 | 2019-2021 | |
| Ocular Therapeutix, INC. | $4,365.29 | 2019-2024 | Dextenza |
| Omeros Corporation | $2,833.34 | 2019-2021 | |
| Ivantis, INC | $2,334.34 | 2019-2021 | |
| Amgen INC. | $2,331.66 | 2024-2025 | Tepezza, Uplizna |
| Tearlab Corp | $2,312.05 | 2020-2022 | |
| Biotissue Holdings INC. | $2,227.97 | 2024-2025 | |
| Carl Zeiss Meditec USA, INC. | $964.08 | 2023-2025 | Veracity Surgical, Quatera 700, Iolmaster 700 |
| Rxsight INC | $575.99 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Thea Pharma INC. | $415.32 | 2022-2025 | Iyuzeh |
| Vertex Pharmaceuticals Incorporated | $375.00 | 2020 | |
| Harrow Eye, LLC | $297.26 | 2024-2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $213.16 | 2024-2025 | Syfovre |
| Beaver-Visitec International, INC. | $169.09 | 2025 | |
| Astellas Pharma Global Development | $143.22 | 2025 | Izervay |
| Astellas Pharma US INC | $55.74 | 2023-2025 | Izervay |
| Horizon Therapeutics Plc | $41.49 | 2022 | |
| Pfizer INC. | $31.92 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Mah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.